Importantly, the fast TAT, low hands-on-time, easy implementation and low training requirements would allow the implementation of plasma-based EGFR detection in a short time thereby enabling the administration of the appropriate treatment in NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.